---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-284633"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:07:44.437207+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enanta Q4 net loss $0.87/sh, revenue $15.1M; cash $188.9M; RSV data positive, STAT6 candidate selected

## Summary
- Net loss $18.7M ($0.87 loss per share) vs $28.8M loss ($1.36/sh) in Q4 2024.
- Total revenue $15.1M from MAVYRET royalties; FY 2025 revenue $65.3M vs $67.6M prior year.
- Ending cash $188.9M; plus $74.8M gross from Oct 2025 offering; runway into FY2029.
- Zelicapavir Phase 2b in high-risk RSV adults met secondary endpoints; 2.2-day symptom resolution improvement.
- Nominated EPS-3903 (STAT6 inhibitor) with >90% pSTAT6 suppression; IND target H2 2026; EDP-978 IND Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-284633
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312525284633/0001193125-25-284633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312525284633/enta-20251117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-284633
- JSON: https://secwatch.observer/filing/0001193125-25-284633.json
- Plain text: https://secwatch.observer/filing/0001193125-25-284633.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.